医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EOS imaging Expands Presence in Asia with First Installation in Hong Kong

2015年05月13日 PM11:53
このエントリーをはてなブックマークに追加


 

PARIS

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the Department of Orthopaedics and Traumatology at the Chinese University of Hong Kong (CUHK) is the first hospital in China to install the EOS system.

Since its founding in 1982, the mission of CUHK’s orthopedics department has evolved into a commitment to provide the highest quality service in patient care, research, education and teaching for medical students and postgraduate training. The department’s clinical work and research has been published in more than 54 international medical journals, contributing to CUHK ranking among the top 100 medical schools in the world, according to Thompson Reuters’, “Times Higher Education World University Subjects Rankings”1.

The university’s decision to adopt an EOS system was guided by the orthopaedic department’s emphasis on patient care and a curriculum designed to train surgeons on industry leading equipment and innovative surgical planning and modeling services.

Prof. Jack Chun-yiu Cheng, Chairman of the Department of Orthopaedics and Traumatology, said, “The orthopaedic clinic at CUHK ceaselessly endeavors to serve the needs and improve the well-being of the patients in Hong Kong and in the global community. By adopting the EOS imaging system, we not only deliver an unmatched standard of care for our patients, but we also ensure that medical students and training surgeons have access to the gold standard in low dose 2D/3D imaging.”

Marie Meynadier, CEO of EOS imaging, said, “The Chinese University of Hong Kong is ranked as a leading university for orthopedic care in Asia and we are thrilled by their decision to adopt EOS® for their diagnosis, planning and control imaging. Adoption of low dose 2D/3D imaging continues to increase in Asia, and this new installation will continue to strengthen our presence in this large and important market.”

The EOS® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Next press release: July 21th, 2015

About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

1http://www.timeshighereducation.co.uk/world-university-rankings/2013-14/subject-ranking/subject/clinical-pre-clinical-health/institution/chinese-university-of-hong-kong

CONTACT

NewCap
Financial communication & Investor relations
Antoine
Denry/ Pierre Laurent
Ph: +33 (0)1 44 71 94 91 – eosimaging@newcap.fr
or
Press
relations (France)

Annie-Florence Loyer: afloyer@newcap.fr
Nadège
Le Lezec: nlelezec@newcap.fr
01
44 71 94 93/ 01 44 71 00 12
or
The Ruth Group (US)
Press
relations / Melanie Sollid-Penton
Ph: 646-536-7023
msollid@theruthgroup.com
or
Anne
Renevot

CFO
Ph: +33 (0)1 55 25 61 24
investors@eos-imaging.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表